Overview

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to determine the safety and effectiveness of islet transplantation, combined with immunosuppressive medications and medications to support islet survival for treating type 1 diabetes in individuals experiencing hypoglycemia unawareness and severe hypoglycemic episodes.
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Anti-Bacterial Agents
Antifungal Agents
Antiviral Agents
Aspirin
Basiliximab
Calcineurin Inhibitors
Clotrimazole
Enoxaparin
Everolimus
Heparin
Miconazole
Pentoxifylline
Sirolimus
Sulfamethoxazole
Tacrolimus
Trimethoprim
Valganciclovir